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The WHO classification system has emerged to distinguish 
between well-differentiated and poorly differentiated neuro-
endocrine neoplasms (NENs) in order to prognostically stratify 
the neuroendocrine tumors (NETs) that are further classified 
according to the TNM classification [1].
Typically, well-differentiated NETs are slow growing mali-
gnancies, of which about 30–60% are metastatic at diagnosis 
and even approximately 30% of patients with completely 
resected localized disease develop metastases during follow-
-up [2]. Except for rare cases of radically resected liver metasta-
ses, distant dissemination of NENs inevitably results in patient 
death. However, in some patients, death is related to heart 
failure in the course of carcinoid heart disease or a massive 
unresectable retroperitoneal desmoplastic reaction. 
Surgery is the only curable treatment for NENs. However, 
the expression of somatostatin receptors on the tumor cell 
surface makes NENs accessible for diagnostic and therapeu-
tic approaches (theranostics) using radiolabeled peptides. 
The first somatostatin receptor imaging (SRI) was performed 
in 1989 with a gamma camera using somatostatin analogs 
radiolabeled with iodine 123 in a patient with a pancreatic 
neuroendocrine tumor. Since that time, SRI has developed and 
numerous studies have demonstrated the superior sensitivity 
of Ga-68-based PET/CT (around 90–100% in most NEN loca-
lizations except for insulinoma). As a result, the current 2017 
ENETS guidelines for radiological, nuclear medicine, and hybrid 
imaging [3] and follow-up of NET [4] guidelines consider SSA-
-PET/CT, if available, as the first-line diagnostic procedure for 
staging and NEN follow-up. A positive SRI scan means lesion 
uptake that is equal to or greater than the liver uptake and is 
a good predictor factor for effective biotherapy and radiola-
beled therapy with somatostatin analogs [5,6]. 
In the present issue of Nowotwory. Journal of Oncology 
Tyrybon et al. presented a case of a patient with low-grade 
NEN of the small intestine who underwent surgery due to 
subileus. Although emergency surgery could suggest an ag-
gressive disease, a retrospective study did not show that the 
signs of bowel obstruction before surgery were a prognostic 
factor of death in small-intestine NET (SI-NET) patients [1, 7]. 
However, emergency surgery is related to a lower number of 
resected lymph nodes and the risk of inappropriate staging [1]. 
This underlines the need for adequate postoperative staging 
using CT and SRI, which is in line with our opinion. Leaving 
the metastatic lymph node and a severe desmoplastic reaction 
may have resulted in relapse in this patient. 
When well-differentiated NETs recur with distant meta-
stases, somatostatin analogs (SAs) are the first-line options 
in most patients except for fast growing tumors or with the 
risk of visceral crisis. For patients with oligometastatic disease, 
SA is the most reasonable treatment option, which results in 
disease stabilization of 12 months. Since SI-NETs have a poor 
response to chemotherapy, TOR inhibitors [8, 9] or radiolabeled 
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somatostatin analogs are the second line of therapy [10]. mTOR 
inhibitors are not reimbursed in Poland. Therefore, radiolabeled 
somatostatin analogs (PRRT) are the only available option with 
an estimated median time of disease stabilization of about 
3 years. High radiopeptide uptake in metastatic disease is the 
predictive factor for long-term response [6].
Of note, during treatment, progression occurs in some 
lesions despite isotope accumulation. If it occurs in a vital 
organ, a patient must be carefully monitored and consulted in 
terms of the possibility of using other cytoreductive therapies. 
In the presented case, progression of recurrence in the heart 
may have resulted in the patient’s death. In oligometastatic 
disease without the symptoms of the carcinoid syndrome 
other causes are unlikely. 
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